LIVN: Keybanc Raises Target
Keybanc maintains overweight rating on LivaNova and raises price target to $92
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.
Keybanc maintains overweight rating on LivaNova and raises price target to $92
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.